In short
A groundbreaking clinical trial is underway to assess the safety, efficacy, and potential benefits of DYNE-251, a new drug designed to treat Duchenne Muscular Dystrophy (DMD). This study focuses on patients with DMD who are suitable for exon 51 skipping, a specific genetic mutation. The trial aims to evaluate how well DYNE-251, administered intravenously, can improve muscle function and increase dystrophin protein levels in patients with this debilitating condition.
At a glance
- Drug Name
- DYNE-251 (Fragment Antibody Targeting Human TfR1 Conjugated to Phosphorodiamidate Morpholino Oligomer)
- Condition
- Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping
- Trial Phase
- Phase 1/2
- Administration
- Intravenous infusion
- Primary Objectives
- Evaluate safety, tolerability, and changes in dystrophin protein levels
- Secondary Objectives
- Assess exon skipping, muscle function, pharmacokinetics, and immunogenicity
- Key Eligibility
- Males aged 4-16 years with confirmed DMD diagnosis amenable to exon 51 skipping
- Study Duration
- Up to 145 weeks (approximately 3 years)
What is DYNE-251?
DYNE-251 is a new medication being developed to treat Duchenne muscular dystrophy (DMD). It is classified as a biological/biotechnological product, which means it is made using living organisms or their products. The active substance in DYNE-251 is called a fragment antibody targeting human TFR1 conjugated to phosphorodiamidate morpholino oligomer. This long name describes the two main parts of the medication: A fragment of an antibody that targets a specific protein in the body called TFR1 A special molecule called a phosphorodiamidate morpholino oligomer (PMO) that is attached to the antibody fragment DYNE-251 is also known by other names, including "Fab targeting human TfR1 conjugated to a PMO".
How Does DYNE-251 Work?
DYNE-251 is designed to work through a process called exon 51 skipping. In patients with DMD, there is a problem with the gene that makes a protein called dystrophin. This protein is crucial for maintaining muscle strength. The exon 51 skipping approach aims to "skip over" the problematic part of the gene, allowing the body to produce a shorter but partially functional version of the dystrophin protein.
The medication is given through intravenous infusion, which means it's delivered directly into the bloodstream through a vein. This method helps ensure that the medication can reach muscles throughout the body.
Target Condition: Duchenne Muscular Dystrophy
DYNE-251 is being developed to treat Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys and is caused by mutations in the dystrophin gene. This gene is responsible for producing the dystrophin protein, which is essential for maintaining the structure and function of muscle fibers.
Clinical Trial Details
DYNE-251 is currently being studied in a Phase 1/2 clinical trial. This means it's in the early stages of testing in humans. The study is designed as a randomized, double-blind, placebo-controlled trial, which helps ensure that the results are as unbiased and accurate as possible. Here are some key details about the trial: It's a multiple ascending dose study, which means different groups of participants will receive increasing doses of the medication to determine the safest and most effective dose. The study will assess the safety, tolerability, pharmacodynamics, efficacy, and pharmacokinetics of DYNE-251. These terms refer to how safe the drug is, how well it's tolerated, what effects it has on the body, how effective it is, and how it's processed by the body. Participants will receive multiple intravenous doses of DYNE-251 over the course of the study.
Eligibility Criteria
The study has specific criteria for who can participate. Some key inclusion criteria are: Boys aged 4 to 16 years Confirmed diagnosis of DMD with a mutation that could benefit from exon 51 skipping Ability to undergo a muscle biopsy Stable dosage of glucocorticoids for at least 12 weeks before starting the study Adequate heart function There are also exclusion criteria, such as: Uncontrolled symptoms of heart failure Recent major surgery or planned surgery during the study Need for daytime ventilator assistance Recent use of other experimental treatments for DMD
Study Objectives
The main objectives of the study are: To evaluate the safety and tolerability of DYNE-251 To measure dystrophin protein levels in muscle tissue after treatment To assess the effectiveness of exon skipping To evaluate muscle function To study how the drug is processed by the body To check for any immune responses to the medication
Potential Benefits
While it's important to note that the effectiveness of DYNE-251 is still being studied, the potential benefits being investigated include: Increased production of dystrophin protein in muscle tissue Improved muscle function Reduced muscle damage (as measured by blood creatine kinase levels) These potential benefits could lead to improved quality of life for patients with DMD, but more research is needed to confirm these effects.
Safety Considerations
As with any new medication, safety is a top priority in the DYNE-251 clinical trial. The study will closely monitor for any side effects or adverse events. Participants will be regularly assessed for: Any new symptoms or health issues that arise during the study Changes in heart and lung function Immune reactions to the medication It's important to remember that as DYNE-251 is still in the early stages of testing, not all potential risks may be known at this time.